C
Contraria Biotech
Develops innovative, cost-effective therapeutic and prophylactic drugs to combat global health challenges like antibiotic resistance, emerging diseases, and pandemics
About Contraria Biotech
Achilles Vaccines operates in the biopharmaceutical sector, focusing on the early-stage development of vaccines and immunotherapeutics. The company leverages a versatile technology platform that utilizes bacteria to produce self-adjuvanting vesicles capable of delivering antigenic molecules. Achilles Vaccines serves clients in the healthcare and pharmaceutical industries, addressing critical needs such as malaria, COVID-19, and bacterial infections. The company employs advanced laboratory and digital technologies, including the NGVR method, to rapidly identify effective vaccine targets. Its business model revolves around research and development, supported by significant seed financing and partnerships, such as the EU Malaria Fund. Revenue is generated through the development and commercialization of biopharmaceutical products, including vaccines and immunotherapeutics.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 11
- Open positions
- None listed
- Dealroom signal
- 33.9/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Oncology, Drug Development, Vaccines, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Jun 2020 | $12M | $48M | European Investment Bank · Bill & Melinda Gates Foundation · Toscana Life Sciences · Fondazione Monte dei Paschi di Siena | — |
Growth signals
Latest recorded traffic for Contraria Biotech is 220 monthly website visits, down 18.5% over the last three months. Contraria Biotech's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Contraria Biotech in the Siena ecosystem
The Contraria Biotech office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
European Investment Bank
Bill & Melinda Gates Foundation
Toscana Life Sciences
Fondazione Monte dei Paschi di Siena
Source: Dealroom Talent Intelligence.
Global footprint
See Contraria Biotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










